Evidence of increased bone loss in patients with severe obstructive sleep apnea supported the potential role of sleep-related hypoxemia on osteoporosis.
The device was the first approved nonpharmacologic treatment for postmenopausal women with low bone density. It has not been tested for ability to reduce fractures.
New research backed up previous findings, showing a substantially higher risk for severe hypocalcemia in older patients on kidney dialysis than in those treated with oral bisphosphonates.
Based on a completed data review, the agency concluded that denosumab increases the risk for severe hypocalcemia in patients with chronic kidney disease.
Though testosterone treatment improves bone strength and structure, a large study on older hypogonadal men showed a high risk for fracture with the treatment.